Disease · MONDO_0002775
anovulation
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. anovulation. Diseases, record MONDO_0002775. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002775
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Approval, for 4 of its 13 drugs, from EMA Human Drugs and PMDA
- Open Targets
Drugs13
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| FOLLITROPIN ALFA | CHEMBL1201692 | Protein | Approval | EMA Human Drugs | 4 | 1 | 1 | Drugs and targets |
| FOLLITROPIN BETA | CHEMBL5315126 | Protein | Approval | PMDA | 2 | 1 | 1 | Drugs and targets |
| CHORIOGONADOTROPIN ALFA | CHEMBL1201464 | Protein | Approval | EMA Human Drugs and PMDA | 2 | 0 | 0 | Drugs and targets |
| FOLLITROPIN DELTA | CHEMBL5315064 | Protein | Approval | EMA Human Drugs | 1 | 0 | 0 | Drugs and targets |
| CLOMIPHENE CITRATE | CHEMBL3185958 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| FOLLITROPIN | CHEMBL4297955 | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets | |
| LETROZOLE | CHEMBL1444 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| GONADOTROPIN, CHORIONIC | CHEMBL1201509 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| CORIFOLLITROPIN ALFA | CHEMBL2108185 | Protein | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LUTROPIN ALFA | CHEMBL1201419 | Protein | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 13
See all 13 drugsTargets57
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| FSHR | Follicle-stimulating hormone receptor | 5 | Follicle stimulating hormone receptor agonist | Approval | https://conductscience.org/library/genes/2492 | Drugs and targets |
| LHCGR | Lutropin-choriogonadotropic hormone receptor | 3 | Luteinizing hormone/Choriogonadotropin receptor agonist | Approval | https://conductscience.org/library/genes/3973 | Drugs and targets |
| ESR1 | Estrogen receptor | 2 | Estrogen receptor alpha agonist; Estrogen receptor alpha modulator | Phase 3 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| COXFA4 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Unknown | https://conductscience.org/library/genes/4697 | Drugs and targets |
| COXFA4L2 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Unknown | https://conductscience.org/library/genes/56901 | Drugs and targets |
| CYP19A1 | Aromatase | 1 | Cytochrome P450 19A1 inhibitor | Phase 3 | https://conductscience.org/library/genes/1588 | Drugs and targets |
| GPD2 | Glycerol-3-phosphate dehydrogenase, mitochondrial | 1 | Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor | Unknown | https://conductscience.org/library/genes/2820 | Drugs and targets |
| LIPF | Gastric triacylglycerol lipase | 1 | Gastric lipase inhibitor | Unknown | https://conductscience.org/library/genes/8513 | Drugs and targets |
| MT-ND1 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Unknown | https://conductscience.org/library/genes/4535 | Drugs and targets |
| MT-ND2 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Unknown | https://conductscience.org/library/genes/4536 | Drugs and targets |
1 to 10 of 57
See all 57 targetsTrials12
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01653743 | Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women | Phase 3 | 81 | 2016-01-07 | Anovulation, Oligo-ovulation, Hypothalamic-pituitary Dysfunction, Polycystic Ovarian Syndrome | FOLLITROPIN ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT02317809 | Bioequivalence Trial of Liquid Versus Freeze-Dried Pergoveris® in Pituitary Suppressed Healthy Premenopausal Female Subjects | Phase 1 | 34 | 2016-12-13 | Healthy | FOLLITROPIN, LUTROPIN ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT01291056 | Differential Effects of Clomiphene Citrate in Women Undergoing Superovulation | Not applicable | 20 | 2016-06-28 | Mood | CLOMIPHENE CITRATE | Its record names the disease | ClinicalTrials.gov |
| NCT02335879 | Phase III Clinical Study of Domestic Recombinant Human Follitropin for Injection to Treat WHO Class II Anovulation | Phase 3 | 534 | Anovulation | FOLLITROPIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00920634 | Protocol for Drug Use Investigation of Follistim Injection (Study P06132)(COMPLETED) | 384 | Anovulation | FOLLITROPIN BETA | Its record names the disease | ClinicalTrials.gov | ||
| NCT02264847 | Human Chorionic Gonadotrophin & Trigger | Phase 3 | 200 | Ovulation Disorder | CLOMIPHENE CITRATE | Its record names the disease | ClinicalTrials.gov | |
| NCT04619914 | the Effect of Clomiphene Citrate Plus Estradiol Valerate Versus Letrozole on Endometrial Thickness and Pregnancy Rate in Infertile Women | Not applicable | 160 | Endometrial Thickness, Pregnancy Rate | CLOMIPHENE CITRATE, ESTRADIOL VALERATE, LETROZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT07143682 | Letrozole Step up Protocol for Ovulation Induction in Infertile Women With Polycystic Ovary Syndrome | Phase 3 | 70 | Polycystic Ovarian Syndrome (PCOS), Infertility | LETROZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT03178500 | Clomiphene Citrate Stair-Step Protocol | Not applicable | 60 | Polycystic Ovary | CLOMIPHENE CITRATE | Its record names the disease | ClinicalTrials.gov | |
| NCT02448459 | COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation (COOL-COS) Associated With Corifollitropin Alfa: a Pilot Study | Phase 1 | 40 | Infertility | CLOMIPHENE CITRATE, CORIFOLLITROPIN ALFA, LETROZOLE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 12
See all 12 trialsComparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| MSJ-0011 vs u-hCG: serious adverse events | 1 of 54 | 0 of 27 | 81 | NCT01653743 | Trial comparisons |
| Liquid Pergoveris vs Freeze-dried Pergoveris: serious adverse events | 1 of 34 | 0 of 31 | 65 | NCT02317809 | Trial comparisons |
| Clomiphene Citrate, Then Placebo vs Placebo, Then Clomiphene Citrate: serious adverse events | 0 of 10 | 0 of 10 | 20 | NCT01291056 | Trial comparisons |
Papers from its trials3
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002775
GET https://conductscience.org/api/diseases/v1/MONDO_0002775/targets?page=2